U.S., April 19 -- ClinicalTrials.gov registry received information related to the study (NCT06934057) titled 'Cabozantinib and Nivolumab Among Older Patients With Renal Cell Carcinoma' on April 09.
Brief Summary: The goal of the study is to describe real-life use and exposition to nivolumab-cabozantinib among older patients with metastatic clear-cell renal cell cancer
Study Start Date: April, 2025
Study Type: INTERVENTIONAL
Condition:
Kidney Cancer
Renal Cell Cancer
Intervention:
DRUG: Nivolumab
Briefly, nivolumab is administered as an approximately 30-minute (240mg every 2 weeks) or 60-minute (480mg every 4 weeks) IV infusion.
DRUG: Cabozantinib
Cabozantinib is a medication that is taken orally every day, once a day away from mea...